Entries / intervention
Local vaginal estrogen
moderate Evidence strength · Status: published · Source agreement: medium
Not medical advice
Menowise aggregates and organizes what the published literature reports, with citations. It does not diagnose, advise, or recommend treatment. Talk to a qualified clinician about your own care.
What the literature reports
Local (vaginal) estrogen is a topical estrogen therapy used for genitourinary symptoms of menopause. The AUA/SUFU/AUGS 2025 Guideline on Genitourinary Syndrome of Menopause reports that patients with recurrent urinary tract infections may be offered local estrogen, with moderate-level evidence supporting its use in reducing infection risk. Local vaginal estrogen is also reported elsewhere as a first-line therapy for GSM. This entry summarizes what the literature reports for navigation and is not medical advice.
Citations
-
AUA / SUFU / AUGS — 2025 Guideline on Genitourinary Syndrome of Menopause — American Urological Association / SUFU / AUGS (Journal of Urology) (2025)
Moderate-level evidence for reducing recurrent UTI risk.
Notes
Maps to entities.yml `vaginal-estrogen` (intervention). Single source (AUA/SUFU/AUGS 2025), so confidence is medium; the guideline itself grades the recurrent-UTI effect as moderate-level evidence, so evidence_strength is moderate. Additional guideline recommendations naming local vaginal estrogen as a first-line therapy for GSM are recorded on the `genitourinary-syndrome-menopause` symptom entry — the intervention and the symptom it treats are kept as distinct entries per profile.
Provenance
This entry is resolved from per-source signals; the raw claims are the audit trail behind it.
- Machine record: /data/sites/vaginal-estrogen.yml (schema-valid, verbatim)
- Signals:
sig-20260710-local-estrogen-recurrent-uti - First recorded 2026-07-10 · last updated 2026-07-10